
Advertise on podcast: The View on GU | with Lalani and Wallis
Rating
5from
This podcast has
48 episodes
Language
EnglishExplicit
No
Date created
2024/01/22
Latest episode
2026/11/05
Average duration
32 min.
Release period
24 days
Description
There is currently a lack of organic multi-disciplinary discussion on what is truly impactful to the field of genitourinary (GU) cancers. The View on GU with Lalani and Wallis is a podcast that will integrate key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians. Importantly, Lalani and Wallis will also discuss the impact of governmental approvals and funding considerations on the GU oncology treatment landscape and provide practical considerations on the management of patients on new-to-market therapies.
Unlock The View on GU | with Lalani and Wallis podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from The View on GU | with Lalani and Wallis podcast
Episode 47: ESMO 2026 Commentary: Prostate Cancer
2026/11/05
Rounding out their three-part coverage from the ESMO 2026 Congress in Madrid, Dr. Aly-Khan Lalani and Dr. Christopher Wallis welcome special guest Dr. Sébastien Hotte to explore the latest developments in prostate cancer research and treatment.
The conversation begins with findings from the DASL-HiCaP trial, examining the role of darolutamide alongside androgen deprivation therapy (ADT) and radiation therapy in very high-risk localized prostate cancer. The discussion also revisits the PROTEUS trial, highlighting new data from its surgical substudy, evolving approaches to treatment intensification, and the importance of multidisciplinary collaboration in optimizing patient care.
Turning to emerging therapies, the panel explores promising early findings involving RIPTAC molecules and their novel mechanism of action. They also review updated evidence from PEACE-1 andquality-of-life findings from the PR.21 trial, considering how these advances may shape treatment decisions in metastatic prostate cancer.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.
Episode 46: ESMO 2026 Commentary: Kidney Cancer
2026/11/05
Continuing their coverage from ESMO 2026 in Madrid, Dr. Aly-Khan Lalani and Dr. Christopher Wallis turn their attention to kidney cancer, highlighting the latest research and emerging approaches to the treatment of renal cell carcinoma (RCC).
The discussion begins with long-term follow-up data from KEYNOTE-564, examining the sustained benefits of adjuvant pembrolizumab and the importance of balancing treatment outcomes with patient experience. They also explore findings from the PE-PE trial, considering the potential role of immunotherapy alongside metastasis-directed treatment in oligometastatic RCC.
Turning to advanced disease, Dr. Lalani and Dr. Wallis review the LITESPARK-012 and LITESPARK-011 trials, discussing treatment combinations, progression-free and overall survival outcomes, and the challenges of balancing efficacy with toxicity. The conversation also highlights emerging research onbispecific T-cell engagers, including early findings from the XmAb819 trial, offering a glimpse into the future of kidney cancer treatment.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.
Episode 45: ESMO 2026 Commentary: Bladder Cancer
2026/11/05
Recorded in Madrid at ESMO 2026, Dr. Aly-Khan Lalani and Dr. Christopher Wallis kick off a three-part series highlighting the latest advances in GU cancer care, beginning with bladder cancer.
With perioperative treatment for muscle-invasive bladder cancer evolving rapidly, Dr. Lalani and Dr. Wallis revisit the NIAGARA trial alongside emerging findings from ENERGIZE and KEYNOTE-866, comparing key trial outcomes and exploring their potential implications for clinical practice.
The conversation also explores emerging ctDNA biomarker data from KEYNOTE-B15/EV-304, new findings from KEYNOTE-905/EV-303, and the highly anticipated VOLGA trial. Dr. Lalani and Dr. Wallis examine the evolving roles of antibody-drug conjugates and immunotherapy, weighing treatment efficacy against potential toxicity, and highlighting the questions that remain around optimizing perioperative care.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.
Episode 44: Multidisciplinary Care and Treatment Optimization in Localized Prostate Cancer
2026/10/01
Dr. Lalani and Dr. Wallis kick off the new academic year with special guest Dr. Alejandro Berlin, a clinician-scientist and radiation oncologist at Princess Margaret Cancer Centre.
This episode highlights multidisciplinary care and treatment optimization in localized prostate cancer, focusing on how specialists collaborate to help patients navigate treatment options and their potential quality-of-life impacts. The conversation also examines the evolution of systemic therapy in high-risk disease, including considerations around the optimal duration of ADT and the integration of ARPIs.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.
Episode 43: ASCO Annual Meeting 2026 Commentary: Bladder Cancer
2026/06/05
Dr. Aly-Khan Lalani and Dr. Chris Wallis dive into the latest bladder cancer breakthroughs, starting with crucial long-term updates from the landmark EV-302 trial. They share encouraging survival data for patients, while exploring which treatments work best if the cancer eventually progresses. The doctors also discuss the future of localized disease, reviewing strategies from the POTOMAC and SAKK trials. By highlighting a range of advanced monitoring tools, they map out how modern care is helping patients safely avoid major surgery while maintaining excellent disease control.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.
Episode 42: ASCO Annual Meeting 2026 Commentary: Kidney Cancer
2026/06/05
Dr. Aly-Khan Lalani and Dr. Chris Wallis discuss how new data from the RAMPART trial strengthens the argument for administering immune-boosting therapies to patients after surgery. This episode also touches on the human side of cancer care, exploring new ways to measure patient side effects and reduce post-treatment regret through improved counseling. The doctors finish the conversation by highlighting a promising new combination of repurposed drugs that is offering renewed hope to young patients fighting Renal Medullary Carcinoma.
This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
Episode 41: ASCO Annual Meeting 2026 Commentary: Prostate Cancer
2026/06/05
Recorded in Chicago, Dr. Aly-Khan Lalani and Dr. Chris Wallis unpack a massive slate of prostate cancer data, fresh from the 2026 ASCO Annual Meeting. The conversation spans the entire disease spectrum, beginning with a deep dive into the PROTEUS trial.
Shifting to advanced disease, Dr. Lalani and Dr. Wallis discuss the TALAPRO-3 and the A-DREAM/Alliance A032101 trials. Concluding with a review of sequencing chemotherapy and radioligand therapy in the PLUDO trial, this episode provides an excellent overview of the prostate cancer landscape presented at ASCO 2026.
This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
Episode 40: Bladder Cancer Masterclass with Dr. Girish Kulkarni (Part 2)
2026/05/11
In Part 2 of the Bladder Cancer Awareness Month series, Dr. Kulkarni, Dr. Lalani and Dr. Wallis examine a "systemic therapy first" approach. Using a real-world patient scenario, the doctors break down the latest clinical trial data and discuss how the surge in neoadjuvant therapy is reshaping everyday decision-making.
The conversation also tackles the unique challenges of Upper Tract Urothelial Carcinoma. From evidence gaps in upper tract care to the complexities of trial design, this episode offers a forward-looking map of the evolving urothelial cancer landscape.
This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
Episode 39: Bladder Cancer Masterclass with Dr. Girish Kulkarni (Part 1)
2026/05/11
From practical risk stratification to the real-world challenges of delivering BCG, Dr. Aly-Khan Lalani and Dr. Christopher Wallis lead a conversation with Dr. Kulkarni about non-muscle invasive bladder cancer and its rapidly evolving treatment landscape.
Dr. Kulkarni is a urologic surgeon at the Princess Margaret Cancer Centre, University Health Network, and a surgeon-scientist and Assistant Professor at the University of Toronto. As a thought leader in bladder cancer, he shares key clinical decision points, patient-centred considerations, and practical strategies that clinicians can apply today.
This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
Episode 38: Genomics 101 in GU Cancers with Dr. Alex Wyatt
2026/04/23
In this episode, Dr. Aly-Khan Lalani, Dr. Christopher Wallis, and Dr. Alex Wyatt walk through the fundamentals of clinical genomics and why it matters for routine practice. They discuss which alterations matter in prostate cancer, germline vs. somatic testing, ctDNA test use cases and limits, and more.
Dr. Alex Wyatt is an Associate Professor in Urologic Sciences and holds the President’s Excellence Chair in Precision Oncology at the University of British Columbia. He is also a Senior Scientist at the Vancouver Prostate Centre and BC Cancer, where his work focuses on advancing clinical genomics and precision oncology in prostate cancer.
This podcast has been made possible through unrestricted financial support by Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
Episode 37: ASCO GU 2026 Commentary: Kidney Cancer
2026/03/06
Dr. Aly-Khan Lalani and Dr. Christopher Wallis also discuss the RAMPART trial, LITESPARK-011, and the K-COMPASS model. This final recap episode highlights how evolving adjuvant strategies and combination sequencing are reshaping the kidney cancer landscape. Be sure to listen to Episodes 35 and 36 for the full ASCO GU recap, covering key updates in prostate and bladder cancer!
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.
Episode 36: ASCO GU 2026 Commentary: Bladder Cancer
2026/03/06
Dr. Aly-Khan Lalani and Dr. Christopher Wallis discuss practice-changing data in non-muscle invasive and muscle-invasive bladder cancer, including perioperative strategies,bladder-sparing approaches, and emerging targeted therapies. Don’t forget to watch or listen to Episode 35 and Episode 37 for updates on prostate and kidney cancer!The View on GU with Lalani & Wallis integrates key clinicaldata from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.
Episode 35: ASCO GU 2026 Commentary: Prostate Cancer
2026/03/06
Dr. Aly-Khan Lalani and Dr. Christopher Wallis also highlight Canadian-led innovation in the GUNS trial and early data from the PAnTHA study, and discuss how Prostate Cancer Working Group 4 may redefine trial design. Episode 35 is the first of three ASCO GU recap episodes, so don’t miss Episode 36 on bladder cancer and Episode 37 on kidney cancer!
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.
Episode 34: The Business of Medical Entrepreneurship with Dr. Neil Fleshner
2026/01/19
In Episode 34, Dr. Aly-Khan Lalani and Dr. Christopher Wallis sit down with Dr. Fleshner to explore how an academic surgeon transitioned from traditional clinical and research roles into medical entrepreneurship. From tackling Canada’s BCG shortage to co-founding a pharmaceutical company that sold for over a billion dollars, Dr. Fleshner walks through how he has built and scaled successful businesses in medicine.
This episode delivers a masterclass on growing your impact beyond the clinic without losing your connection to medicine.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by AbbVie, Astellas, Ipsen, and Merck.
Episode 33: How Mentorship Shapes Medicine with Dr. Daniel Heng
2025/12/18
In Episode 33, Dr. Aly-Khan Lalani and Dr. Christoper Wallis sit down with Dr. Daniel Heng, Clinical Professor at the University of Calgary and Head of Medical Oncology at the Arthur J.E. Child Comprehensive Cancer Centre. Together, they explore the full landscape of mentorship and sponsorship in academic medicine, from what makes an exceptional mentee to how leaders identify and support rising talent.
The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
This podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.
Podcast reviews
Read The View on GU | with Lalani and Wallis podcast reviews
Podcast sponsorship advertising
Start advertising on The View on GU | with Lalani and Wallis relevant audience podcasts
You may also like to advertise on these Podcasts

4.947999419
The Shawn Ryan Show
Shawn Ryan

4.5185359
Who, When, Wow!
Tinkercast | Wondery

4.6688781131
Armchair Expert with Dax Shepard
Armchair Umbrella

4.9554862201
The MeidasTouch Podcast
MeidasTouch Network

4.639655
Only Murders in the Building Podcast
Straw Hut Media

4.7833521
The Home Service Expert Podcast
Tommy Mello: $200 Million Founder|Forbes, Inc., Entrepreneur Columnist

4.443671371
Something You Should Know
Mike Carruthers | OmniCast Media

4.7906254
Everything is Fine
Jennifer Romolini and Kim France

4.610916582
Serialously with Annie Elise
Annie Elise & Audioboom Studios

4.41171483
The Outlier Health Podcast
Matt Frazier, Matt Tullman, Isabelle Caputo, and Doug Hay